A REVIEW OF ABBV-744 IN COMBINATION WITH IMMUNOTHERAPY

In Segment A, contributors will get diverse doses and schedules of oral ABBV-744 tablet to identify safe dosing program. Added individuals will probably be enrolled at the identified monotherapy dosign routine. In Segment B, members will obtain oral ruxolitinib and ABBV-744 will be specified as "insert-on" therapy. In Segment C, contributors will o